Everolimus denied for failing step therapy by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Requires Step Therapy for Everolimus — and How to Override It

Everolimus is used in serious conditions including certain cancers, tuberous sclerosis complex, and transplant rejection prophylaxis. Kaiser's step-therapy requirement means the plan will not authorize everolimus until documentation shows that one or more alternative therapies were tried first and either failed or are clinically inappropriate for this patient. This is a common prior-authorization hurdle for specialty drugs, but it is directly appealable — and state and federal law provide important override rights when prior stepping is not clinically appropriate.

## The Federal Appeal Framework

Under ACA §2719, step-therapy denials are fully appealable internally and then through independent external review (IRO), with an external review window of four months after final internal denial. For urgent oncology or transplant cases, request expedited review immediately.

For self-funded employer plans, ERISA §503 applies: you are entitled to the specific step-therapy criteria applied, all clinical guidelines relied upon, and a full-and-fair review.

Many states — including California, where Kaiser operates most extensively — have enacted step-therapy override laws requiring plans to grant exceptions when: (a) the required step drug was tried and failed; (b) the required step drug is contraindicated or clinically inappropriate for this individual patient; or (c) starting with the step-therapy drug would cause harm or delay. Identify whether your state law applies and cite it explicitly in the appeal.

## Documentation to Gather

• Prior therapy records: Dated pharmacy fill history, infusion records, and office notes for every therapy Kaiser lists as required prior to everolimus — showing start date, duration, clinical response, and reason for discontinuation or inadequacy.
• Clinical exception documentation: If a required step-therapy agent was never tried because it is inappropriate for this patient, the prescriber's chart notes and letter explaining the individual clinical reason (not a general population statement).
• Diagnosis, staging, and disease-progression records: Pathology, imaging, biomarker testing, and clinical notes showing disease status and urgency of treatment.
• Prescriber's step-therapy override letter: A letter explicitly addressing each step-therapy requirement in Kaiser's policy, with chart citations showing each step was completed or why a clinical exception applies.
• FDA prescribing label for everolimus: The indication section matching this patient's condition.
• Applicable specialty guideline: Reference to the relevant NCCN or specialty society guideline supporting everolimus for this patient's condition and situation.

## Criteria-Mapping Structure

| Kaiser Step-Therapy Requirement | Patient Chart Evidence or Exception Basis | |---|---| | [Copy each required step verbatim from Kaiser's clinical policy] | [Dated chart note, pharmacy record, or clinical exception documented in chart] |

## Practical Next Steps

1. Request Kaiser's clinical policy for everolimus listing each step-therapy requirement. 2. Audit the patient's medication history against every required step. 3. Have the treating specialist write a letter addressing each step individually — confirming completion, failure, or documented clinical exception. 4. Research whether your state has a step-therapy override law and cite it in the appeal if applicable. 5. File the internal appeal with the criteria-mapping table and complete prior-therapy documentation. 6. If denied internally, escalate immediately to independent external review — IRO reviewers assess whether step requirements were met using objective clinical standards, not just the plan's internal policy preferences.